Fluvoxamine versus other anti‐depressive agents for depression
Citation: Omori I.M., Watanabe N., Nakagawa A., et al. Fluvoxamine versus other anti‐depressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD006114. DOI: 10.1002/14651858.CD006114.pub2
No strong evidence was found to suggest that fluvoxamine was superior or inferior to other antidepressants in the acute phase treatment of depression.
Fluvoxamine is one of the oldest selective serotonin reuptake inhibitors (SSRIs) and is prescribed to patients with major depression in many countries. This review evaluates the effectiveness, tolerability and side effect profile of fluvoxamine for major depression in comparison with other anti‐depressive agents. A random effects model was used to combine information from 54 randomised controlled trials (4353 study participants) that met inclusion criteria. A further meta-analysis was conducted on 49 of these studies. Overall, no strong evidence was found to indicate that fluvoxamine was either superior or inferior to other antidepressants regarding response, remission and tolerability. However, differing side effect profiles were evident, especially regarding gastrointestinal side effects of fluvoxamine when compared to tricyclic antidepressants (TCAs).
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the health of refugees and asylum seekers but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the health of refugees and asylum seekers on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.